The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer's diagnosis in diabetes patients.

Nearly 7 million Americans 65 and older are living with Alzheimer’s disease, which gradually destroys memory and thinking skills and the ability to perform daily tasks.

The active ingredient found in popular medications for Type 2 diabetes and weight loss, including Ozempic and Wegovy, may reduce the risk of Alzheimer's disease, a new study published Thursday finds.

Semaglutide is a glucagon-like peptide-1 (GLP-1) drug, and is the active agent in Ozempic and its weight-loss cousin, Wegovy. These medications mimic the GLP-1 hormone, which helps control insulin and blood sugar levels, decreases appetite and slows digestion of food.

Patients taking Novo Nordisk A/S’s Ozempic were at significantly reduced risk of being diagnosed with Alzheimer’s, according to new research that adds to the evidence surrounding the drug’s effects in diseases beyond type 2 diabetes and obesity.

Semaglutide, the active ingredient in Ozempic and Wegovy, appeared to reduce the risk of Alzheimer’s disease in people with Type 2 diabetes, according to a study published Thursday in the journal Alzheimer’s & Dementia.

In an observational study, Novo Nordisk’s drug Ozempic was linked to a lower risk of getting diagnosed with Alzheimer’s among people with type 2 diabetes.